# Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

> **NCT01088880** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (estimated)

## Conditions studied

- Familial Mediterranean Fever

## Interventions

- **DRUG:** Canakinumab

## Key facts

- **NCT ID:** NCT01088880
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2012-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01088880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01088880, "Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01088880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*